CS Medica Salute del bilancio

Salute finanziaria criteri di controllo 0/6

CS Medica ha un patrimonio netto totale di DKK1.8M e un debito totale di DKK12.3M, che porta il suo rapporto debito/patrimonio netto a 676.5%. Le sue attività totali e le sue passività totali sono rispettivamente DKK34.2M e DKK32.3M.

Informazioni chiave

676.5%

Rapporto debito/patrimonio netto

DKK 12.30m

Debito

Indice di copertura degli interessi	n/a
Contanti	DKK 51.95k
Patrimonio netto	DKK 1.82m
Totale passività	DKK 32.35m
Totale attività	DKK 34.17m

Aggiornamenti recenti sulla salute finanziaria

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Jun 04

Recent updates

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Jun 04

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { CSMED di DKK4.9M ) non coprono le sue passività a breve termine ( DKK18.4M ).

Passività a lungo termine: Le attività a breve termine di CSMED ( DKK4.9M ) non coprono le sue passività a lungo termine ( DKK13.9M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 673.6% ) di CSMED è considerato alto.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di CSMED si sia ridotto negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: CSMED ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: CSMED ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 13.3 % ogni anno

CS Medica Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

New major risk - Market cap size

CS Medica A/S Announces Approval of CANNASEN Pain Patch in Malaysia and Trademark Registration in Thailand

Third quarter 2024 earnings released

CS MEDIC Receives "Intention to Grant" for European Patent Application Concerning Cannasen® Psoriasis Gel, Reinforcing Leadership in Cbd-Infused Dermatological Innovations

CS Medica A/S to Report Q3, 2024 Results on Jul 31, 2024

CS Medica (NGM:CSMED) Is Making Moderate Use Of Debt

Second quarter 2024 earnings released

CS Medica A/S to Report Fiscal Year 2024 Results on Nov 28, 2024

CS Medica A/S Breaks Through Asian Market Barrier with Approval of Protective Nasal Gel in Malaysia

CS Medica A/S to Report 3 Months Period Ending Dec 31, 2023 Results on Mar 29, 2024

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report 3 Months 2023 Final Results on Apr 24, 2024

CS Medica A/S Announces FDA Authorization for Commercialization for Eight Products in the U.S. Market

Full year 2023 earnings released: kr.1.18 loss per share (vs kr.0.93 loss in FY 2022)

CS Medica A/S to Report Q4, 2024 Results on Nov 14, 2024

Cs Medica A/S Announces Indian State's Fda Approval for Two Cosmetic Products

New major risk - Share price stability

New major risk - Market cap size

CS Medica A/S to Report Q3, 2023 Results on Aug 08, 2023

CS Medica A/S to Report Q3, 2023 Results on Jul 18, 2023

CS Medica A/S Secures Future Compliance with New Medical Device Regulation Through Signed Contract with Notify Body

New major risk - Market cap size

CS Medica A/S Announces Positive Results from Clinical Trial of Nasal Protect Gel for Hay Fever/Allergic Rhinitis

CS Medica A/S to Report Fiscal Year 2022 Final Results on Jan 27, 2023

CS Medica A/S to Report Q1, 2023 Results on Feb 17, 2023

CS Medica A/S, Annual General Meeting, Feb 09, 2023

CS Medica A/S Provides Update on Clinical Trials

Full year 2022 earnings released: kr.0.90 loss per share (vs kr.0.059 profit in FY 2021)

No independent directors

CS Medica A/S and CanNordic A/S Announce the Resignation of Bo Unéus as Board Member

CS Medica A/S Provides Revenue Guidance for the Year 2022

CS MEDICA Provides Patent Update

CS Medica A/S to Report Fiscal Year 2022 Results on Nov 18, 2022

CS MEDICA A/S Reports Proof of Concept in the Results from the Clinical Trial on NGP-01 (Cannasen®Cbd Psoriasis Gel) Against Placebo

CS MEDICA A/S Announces Groundbreaking Discovery in the Natural Cannabinoid CBD's Activity in the Body

Cs Medica Announces Positive Clinical Trial Results from the Final Report on Nga-01 Gel & Nsa-01 Capsule in Combination Against Placebo

CS Medica A/S Reports the Results from the Clinical Trial on NGA-01(CANNASEN®CBD Arthritis Gel) Against Placebo

CS MEDICA A/S Provides Revenue Guidance for 2023/2024

No independent directors

CS Medica Receives the Final Approval from Hong Kong Customs, the Drug Registration Office

CS MEDICA A/S Provides Patent Update

CS MEDICA A/S Finalizes THC Test At PPB Level on Their Cannasen®Cbd Products to Comply with the Strict Regulations on the Asian Market

CS MEDICA A/S Appoints Heidi Ahlefeldt-Laurvig as Chief Growth Officer and Chief Marketing Officer, Effective May 1, 2022

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

CS MEDICA A/S Reaffirms Revenue Guidance for the Fiscal Year 2022

CS MEDICA A/S Announces Their CANNANSEN®CBD Anti-Hair Loss Serum Approves in the United Arab Emirates

CS MEDICA A/S Announces an Additional Five Intellectual Property Rights Registrations

No independent directors

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane